SCHEDULE 13G/A: Biotechnology Value Fund Entities Disclose Significant Stake in Cidara Therapeutics, Reaching 9.99% Beneficial Ownership

Multiple entities associated with Biotechnology Value Fund have filed an amended Schedule 13G, revealing an aggregate beneficial ownership of 9.99% in Cidara Therapeutics, Inc. as of December 31, 2024.

Summary

• As of December 31, 2024, various entities and individuals associated with Biotechnology Value Fund (BVF) collectively beneficially owned 1,093,499 shares of Cidara Therapeutics, Inc. common stock.
• This aggregate ownership represents approximately 9.99% of Cidara Therapeutics' outstanding shares, calculated based on 10,945,235 shares outstanding as of December 20, 2024, plus 703 shares underlying certain pre-funded warrants.
• The reporting group includes Biotechnology Value Fund, L.P. (BVF) and BVF I GP LLC, each beneficially owning 495,174 shares (4.5%).
• Biotechnology Value Fund II, L.P. (BVF2) and BVF II GP LLC each beneficially owned 489,056 shares (4.5%).
• Biotechnology Value Trading Fund OS LP and BVF Partners OS Ltd. each beneficially owned 63,450 shares (0.6%).
• BVF GP Holdings LLC beneficially owned 984,230 shares (9.0%).
• BVF Partners L.P., BVF Inc., and Mark N. Lampert are deemed to beneficially own the full 1,093,499 shares (9.99%).
• The reporting persons also hold 280,869 Pre-Funded Warrants, 2,104,472 shares of Series X convertible preferred stock, and 14,857 shares of Series A convertible preferred stock, but conversion limitations (9.99% blocker) prevent the immediate conversion of most of these securities into common stock.
• Specifically, only 703 shares underlying Pre-Funded Warrants were convertible as of December 31, 2024, while all Series X and Series A preferred stock conversions were prohibited due to the 9.99% beneficial ownership limitation.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It provides no positive or negative operational or financial news about the issuer, only details about an investor's stake.

Risks

• The beneficial ownership of Pre-Funded Warrants, Series X Preferred Stock, and Series A Preferred Stock is subject to a 9.99% conversion limitation, meaning the holders cannot convert these securities if it would result in beneficial ownership exceeding 9.99% of the outstanding common stock.
• As of December 31, 2024, this limitation prohibited the conversion of most Pre-Funded Warrants (280,166 out of 280,869) and all Series X and Series A Preferred Stock held by the reporting persons and managed accounts, limiting their ability to increase their common stock holdings through conversion.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of significant ownership by an investment fund specializing in biotechnology, indicating a notable institutional interest in Cidara Therapeutics, Inc. It does not provide broader industry trends but highlights a specific investment position within the biotechnology sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant 9.99% stake by a specialized biotechnology investment fund may be viewed positively by some shareholders as it indicates institutional confidence or interest in the company. However, the inability to convert additional preferred shares due to ownership limitations might cap potential future increases in the fund's common stock stake.

Key Dates

Keywords

Cidara Therapeutics, Biotechnology Value Fund, SEC Filing, Schedule 13G, Beneficial Ownership, Common Stock, Preferred Stock, Pre-Funded Warrants, Institutional Investor, Shareholder Disclosure, Biotechnology, Investment Fund